GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (OTCPK:ATOWW) » Definitions » Net Income Including Noncontrolling Interests

ATOWW (Atossa Therapeutics) Net Income Including Noncontrolling Interests : $-26.34 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Atossa Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Atossa Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was $-6.72 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was $-26.34 Mil.

Atossa Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Atossa Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Net Income Including Noncontrolling Interests Chart

Atossa Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.83 -20.61 -26.96 -30.09 -25.50

Atossa Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.88 -6.05 -7.23 -6.35 -6.72

Atossa Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (OTCPK:ATOWW) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
VXRT ACHV NMRA AGEN OBIO SGMT ASMB SAVA BDTX SGMO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ATOS:USA ATOS:Mexico YAG2:Germany YAG2:Germany
Address
10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125
Website
https://www.atossatherapeutics.com
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.